Non-Coding RNA Polymorphisms (rs2910164 and Rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy

Overview

Journal Front Pharmacol

Date 2021 Oct 4

PMID 34603024

Citations 4

Authors

Yi-Xin Chen

Juan Chen

Ji-Ye Yin

Hong-Hao Zhou

Bai-Mei He

Zhao-Qian Liu

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the largest cause of cancer deaths in the world. Platinum-based chemotherapy is a foundation of first-line chemotherapy. However, the prognosis of lung cancer treated with platinum-based chemotherapy is still a challenge. Single nucleotide polymorphism of non-coding RNA has the potential to be a biomarker, but its effectiveness has yet to be comprehensively assessed. In this study, we explored the association between polymorphisms of non-coding RNA and prognosis of lung cancer patients receiving platinum-based chemotherapy. For 446 lung cancer patients receiving platinum-based chemotherapy, 22 single nucleotide polymorphisms of microRNA and long noncoding RNA were genotyped by MALDI-TOF mass spectrometry. Cox regression analysis, Kaplan-Meier method, and long-rank test have been performed to assess the association of overall and progression-free survival with polymorphisms. In the additive and dominant models, genetic polymorphism of rs1333049 (G > C) was significantly associated with progression-free survival. Additive model: CC vs GC vs GG [HR = 0.84, = 0.021, 95% CI (0.73-0.97)]; Recessive model: CC vs GG + GC [HR = 0.77, = 0.026, 95% CI (0.61-0.97)]. In the dominant model, compared with the CC genotype patients, lower risk of death [HR = 0.81, = 0.036, 95% CI (0.66-0.99)] and lower risk of progression [HR = 0.81, = 0.040, 95% CI (0.67-0.99)] have been observed on the patients with CG or GG genotype in rs2910164. Our research demonstrated the potential of using rs1333049 (G > C) and rs2910164 (C > G) as biomarkers to support the prediction of a better prognosis for lung cancer patients receiving platinum-based chemotherapy.

Citing Articles

The effects of ANRIL polymorphisms on colorectal cancer, tumor stage, and tumor grade among Iranian population.

Asadi-Tarani M, Darashti A, Javadi M, Rezaei M, Saravani M, Salimi S Mol Biol Rep. 2024; 51(1):486.

PMID: 38578390 DOI: 10.1007/s11033-024-09420-w.

Association of Genetic Polymorphisms and Serum Levels of miR-1-3p with Postoperative Mortality following Abdominal Aortic Aneurysm Repair.

Li T, Jiang B, Wu Y, Yang J, Ma C, Yuan Y J Clin Med. 2023; 12(3).

PMID: 36769594 PMC: 9917931. DOI: 10.3390/jcm12030946.

lncRNASNP v3: an updated database for functional variants in long non-coding RNAs.

Yang Y, Wang D, Miao Y, Wu X, Luo H, Cao W Nucleic Acids Res. 2022; 51(D1):D192-D198.

PMID: 36350671 PMC: 9825536. DOI: 10.1093/nar/gkac981.

Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events.

Ivanova E, Asadullina D, Rakhimov R, Izmailov A, Izmailov A, Gilyazova G Noncoding RNA Res. 2022; 7(3):159-163.

PMID: 35846077 PMC: 9263420. DOI: 10.1016/j.ncrna.2022.06.004.

References

Fang C, Li X, Gong W, Wu N, Tang J, Yin J . Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy. Clin Exp Pharmacol Physiol. 2016; 44 Suppl 1:21-29. DOI: 10.1111/1440-1681.12704. View

Liz J, Esteller M . lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2015; 1859(1):169-76. DOI: 10.1016/j.bbagrm.2015.06.015. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Veneziano D, Marceca G, Di Bella S, Nigita G, Distefano R, Croce C . Investigating miRNA-lncRNA Interactions: Computational Tools and Resources. Methods Mol Biol. 2019; 1970:251-277. DOI: 10.1007/978-1-4939-9207-2_14. View

Wang D, Wang Y, Lin Z, Cai L . Association between miRNA-146a polymorphism and lung cancer susceptibility: A meta-analysis involving 6506 cases and 6576 controls. Gene. 2020; 757:144940. DOI: 10.1016/j.gene.2020.144940. View

Ghobadi N, Mehramiz M, Shahidsales S, Rezaei Brojerdi A, Anvari K, Khazaei M . A genetic variant in CDKN2A/2B locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma. J Cell Physiol. 2018; 234(4):5070-5076. DOI: 10.1002/jcp.27310. View

Ryan B, Robles A, Harris C . Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010; 10(6):389-402. PMC: 2950312. DOI: 10.1038/nrc2867. View

Yuan F, Zhang S, Xie W, Yang S, Lin T, Chen X . Effect and mechanism of miR-146a on malignant biological behaviors of lung adenocarcinoma cell line. Oncol Lett. 2020; 19(6):3643-3652. PMC: 7202298. DOI: 10.3892/ol.2020.11474. View

Yoon K, Yoon H, Park S, Jang H, Zo J, Lee H . The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012; 144(4):794-807. DOI: 10.1016/j.jtcvs.2012.06.030. View

10.

Dykes I, Emanueli C . Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. Genomics Proteomics Bioinformatics. 2017; 15(3):177-186. PMC: 5487525. DOI: 10.1016/j.gpb.2016.12.005. View

11.

Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z . MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013; 518(2):351-9. DOI: 10.1016/j.gene.2012.12.103. View

12.

Hao X, Xia L, Qu R, Yang X, Jiang M, Zhou B . Association between miR-146a rs2910164 polymorphism and specific cancer susceptibility: an updated meta-analysis. Fam Cancer. 2017; 17(3):459-468. DOI: 10.1007/s10689-017-0056-0. View

13.

Seifi S, Pouya F, Rahmani M, Mehramiz M, Rastgar-Moghadam A, Gharib M . Association of cyclin-dependent kinase inhibitor 2A/B with increased risk of developing breast cancer. J Cell Physiol. 2019; 235(6):5141-5145. DOI: 10.1002/jcp.29388. View

14.

Motterle A, Pu X, Wood H, Xiao Q, Gor S, Ng F . Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet. 2012; 21(18):4021-9. PMC: 3428153. DOI: 10.1093/hmg/dds224. View

15.

Shi J, Wang L, Wu N, Li J, Hui Z, Liu S . Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer. 2019; 128:91-100. DOI: 10.1016/j.lungcan.2018.11.031. View

16.

Liu C, Fu X, Xia M, Zhang Q, Gu Z, Guo A . miRNASNP-v3: a comprehensive database for SNPs and disease-related variations in miRNAs and miRNA targets. Nucleic Acids Res. 2020; 49(D1):D1276-D1281. PMC: 7778889. DOI: 10.1093/nar/gkaa783. View

17.

Jazdzewski K, Murray E, Franssila K, Jarzab B, Schoenberg D, de la Chapelle A . Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008; 105(20):7269-74. PMC: 2438239. DOI: 10.1073/pnas.0802682105. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Hong M, Choi Y, Jang J, Jung H, Lee S, Lee W . Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC. J Thorac Oncol. 2013; 8(6):703-10. DOI: 10.1097/JTO.0b013e318288dc0a. View

20.

Gong W, Peng J, Yin J, Li X, Zheng W, Xiao L . Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol Sin. 2017; 38(4):581-590. PMC: 5386317. DOI: 10.1038/aps.2016.164. View